Amgen to offer senior notes in tranches due 2028, 2032, 2041, 2052; talk emerges

By Marisa Wong and Cristal Cody

Los Angeles, Aug. 5 – Amgen Inc. plans to price senior notes in four tranches due 2028, 2032, 2041 and 2052 (A-), according to a 424B3 filing with the Securities and Exchange Commission.

The notes due Aug. 9, 2028 are talked with a spread in the Treasuries plus 85 basis points to 90 bps area, a market source detailed.

A tranche due Jan. 15, 2032 is being marketed with talk in the Treasuries plus 100 bps to 105 bps area.

Spread talk on the tranche due Aug. 9, 2041 is in the Treasuries plus 120 bps to 125 bps area.

And, the longest-dated tranche, the notes due Jan. 15, 2052 have talk in the Treasuries plus 130 bps to 130 bps area.

The notes will have make-whole calls and par calls a number of months before each maturity date.

Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, Barclays and Goldman Sachs & Co. LLC are the joint bookrunners.

Proceeds will be used to repay debt maturities due in 2022 and for general corporate purposes.

The biopharmaceutical company is based in Thousand Oaks, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.